Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $278.6M as of September 30, 2024 to fund its operations into 2026.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: